Loading
Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer.
Nicoletta Colombo was principal investigator of KEYNOTE-826, which showed pembrolizumab added to chemotherapy with or without bevacizumab improves survival in persistent, recurrent or metastatic cervical cancer, the first immunotherapy survival gain in the disease. She has chaired ESMO-ESGO ovarian cancer consensus conferences and led MITO and ENGOT trials. She directs gynaecologic oncology at IEO.
Shares PD-1, Cervical cancer, Ovarian cancer, Pembrolizumab and the tags cervical, immunotherapy.
Shares KEYNOTE-826, VEGF / VEGFR, PD-1, Cervical cancer and the tag cervical.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares VEGF / VEGFR, PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares European Society of Gynaecological Oncology, Cervical cancer, Ovarian cancer.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares the tags immunotherapy, guidelines.